These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 30502777)

  • 61. [Priority setting for the health technology assessment].
    Poblete-Vargas S; Castillo-Laborde C
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S22-6. PubMed ID: 24861176
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Resource allocation and health technology assessment in Australia: views from the local level.
    Gallego G; van Gool K; Kelleher D
    Int J Technol Assess Health Care; 2009 Apr; 25(2):134-40. PubMed ID: 19331706
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evidence-based decision making in healthcare in Central Eastern Europe.
    Ferrario A; Baltezarević D; Novakovic T; Parker M; Samardzic J
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):611-5. PubMed ID: 25090222
    [No Abstract]   [Full Text] [Related]  

  • 64. HEALTH TECHNOLOGY ASSESSMENT IN CENTRAL, EASTERN, AND SOUTH EUROPEAN COUNTRIES: CROATIA.
    Huic M; Tandara Hacek R; Svajger I
    Int J Technol Assess Health Care; 2017 Jan; 33(3):376-383. PubMed ID: 28803589
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Integration of health technology assessment recommendations into organizational and clinical practice: A case study in Catalonia.
    Gagnon MP; Sánchez E; Pons JM
    Int J Technol Assess Health Care; 2006; 22(2):169-76. PubMed ID: 16571192
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Involving patients, the insured and the general public in healthcare decision making].
    Mühlbacher AC; Juhnke C
    Z Evid Fortbild Qual Gesundhwes; 2016; 110-111():36-44. PubMed ID: 26875034
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Thai health technology assessment guideline development.
    Teerawattananon Y; Chaikledkaew U
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S11-5. PubMed ID: 19253483
    [TBL] [Abstract][Full Text] [Related]  

  • 69. HEALTH TECHNOLOGY ASSESSMENT IN TURKEY.
    Kahveci R; Koç EM; Küçük EÖ
    Int J Technol Assess Health Care; 2017 Jan; 33(3):402-408. PubMed ID: 28595660
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Health technologies for rare diseases: does conventional HTA still apply?
    Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):315-7. PubMed ID: 24702042
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The Netherlands.
    Banta D; Oortwijn WJ
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():143-7. PubMed ID: 19538813
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Identifying economic evaluations for health technology assessment.
    Glanville J; Paisley S
    Int J Technol Assess Health Care; 2010 Oct; 26(4):436-40. PubMed ID: 20942986
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Economic evaluations conducted by Canadian health technology assessment agencies: where do we stand?
    Tarride JE; McCarron CE; Lim M; Bowen JM; Blackhouse G; Hopkins R; O'Reilly D; Xie F; Goeree R
    Int J Technol Assess Health Care; 2008; 24(4):437-44. PubMed ID: 18828938
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Value Assessment Frameworks for HTA Agencies: The Organization of Evidence-Informed Deliberative Processes.
    Baltussen R; Jansen MPM; Bijlmakers L; Grutters J; Kluytmans A; Reuzel RP; Tummers M; der Wilt GJV
    Value Health; 2017 Feb; 20(2):256-260. PubMed ID: 28237205
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Using health technology assessment to support evidence-based decision-making in Canada: an academic perspective.
    Xie F; Bowen JM; Sutherland SC; Burke N; Blackhouse G; Tarride JE; O'Reilly D; Goeree R
    Expert Rev Pharmacoecon Outcomes Res; 2011 Oct; 11(5):513-21. PubMed ID: 21958096
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Development and test of a decision support tool for hospital health technology assessment.
    Sampietro-Colom L; Morilla-Bachs I; Gutierrez-Moreno S; Gallo P
    Int J Technol Assess Health Care; 2012 Oct; 28(4):460-5. PubMed ID: 23062518
    [TBL] [Abstract][Full Text] [Related]  

  • 77. From idealistic rookies to a regional leader: the history of health technology assessment in Poland.
    Nizankowski R; Wilk N
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():156-62. PubMed ID: 19527537
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Health technology assessment of medical devices: a survey of non-European union agencies.
    Ciani O; Wilcher B; Blankart CR; Hatz M; Rupel VP; Erker RS; Varabyova Y; Taylor RS
    Int J Technol Assess Health Care; 2015 Jan; 31(3):154-65. PubMed ID: 26044729
    [TBL] [Abstract][Full Text] [Related]  

  • 79. HTA Implementation in Latin American Countries: Comparison of Current and Preferred Status.
    Rosselli D; Quirland-Lazo C; Csanádi M; Ruiz de Castilla EM; González NC; Valdés J; Abicalaffe C; Garzón W; Leon G; Kaló Z
    Value Health Reg Issues; 2017 Dec; 14():20-27. PubMed ID: 29254537
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Relevance of barriers and facilitators in the use of health technology assessment in Colombia.
    Dams F; Gonzalez Rodriguez JL; Cheung KL; Wijnen BFM; Hiligsmann M
    J Med Econ; 2018 May; 21(5):510-517. PubMed ID: 29513062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.